{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/depression/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"69de9fdc-1e49-5a89-8dc8-72e207b8e9d1","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 5a13b816-66de-4d85-9eca-e78ffa753099 --><h2>Changes</h2><!-- end field 5a13b816-66de-4d85-9eca-e78ffa753099 -->","summary":null,"htmlStringContent":"<!-- begin item 053a25d8-1a8f-4eb8-b02c-6416ae563785 --><!-- begin field 339e5861-12f4-4698-b61f-8b8914be1409 --><p><strong>February 2021 </strong>— minor update. SSRI drug interactions updated in line with manufacturer's SPC for sertraline.</p><p><strong>January 2021 </strong>— minor update. A typographical error has been corrected.</p><p><strong>September 2020 </strong>— minor update. Gastrointestinal adverse effects of SSRIs have been updated in line with manufacturer's SPC for paroxetine.</p><p><strong>August 2020 </strong>— minor update. Broken URL links updated.</p><p><strong>July 2020 </strong>— minor update. SNRI cardiac adverse effects updated in line with manufacturer's SPC for venlafaxine.</p><p><strong>May 2020</strong> — minor update. SSRI drug interactions updated in line with manufacturer's SPC for citalopram.</p><p><strong>March 2020 </strong>— minor update. Takotsubo cardiomyopathy has been added as an adverse effect of SNRIs in line with updated manufacturer's SPC.<br><strong><br>March 2020</strong> —  minor update. A typo in the table in the section on prescribing antidepressants in people with chronic physical health problems has been removed.</p><p><strong>February 2020</strong> — minor update. Reference to a clinical guideline has been removed from the basis for recommendation in the diagnosis section of this topic.</p><p><strong>December 2019</strong> — reviewed. A literature search was conducted in December 2019 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. Structural changes have been made, but there have been no changes to the recommendations in this topic.</p><!-- end field 339e5861-12f4-4698-b61f-8b8914be1409 --><!-- end item 053a25d8-1a8f-4eb8-b02c-6416ae563785 -->","topic":{"id":"5f794dff-eed8-52d6-bb65-1b1a9b1fc50a","topicId":"1b270734-f24e-4b58-8355-adaec350f356","topicName":"Depression","slug":"depression","lastRevised":"Last revised in February 2021","chapters":[{"id":"b34732f5-da05-5558-ac7e-4169aea1302d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bd7d7dbf-c3a1-5690-8d7b-8fe76ab04a16","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"cd426153-dec3-52c5-a8ab-af99800c0ec3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"69de9fdc-1e49-5a89-8dc8-72e207b8e9d1","slug":"changes","fullItemName":"Changes"},{"id":"a3c07602-3d45-5287-8c9a-8f9efd7a336a","slug":"update","fullItemName":"Update"}]},{"id":"f87fe236-c4f0-50f8-b694-28b5778f138d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f1acf59a-ed11-5fb0-afc0-cee8532f5512","slug":"goals","fullItemName":"Goals"},{"id":"e98a7293-7a01-5fcc-9e1a-89b044ef1a02","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4182b8a5-9b8d-55e9-a4d9-fad2ca31d873","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c55afa55-15bf-5a19-94a8-21ab0c17f7b7","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a6e7d7a8-fed0-5900-aab1-c863964e870a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"72e01363-0933-5668-b378-6249cb2b64f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d36d2b88-dd20-5f53-882c-81e310273361","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"6358ea37-2401-503d-97aa-9d7fa8d3914d","slug":"definition","fullItemName":"Definition"},{"id":"d34c93b9-e882-588a-8711-b0acdcba167b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f8f0d70d-670c-5aae-8508-7f5d3871c3ee","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6b8dc395-d0cf-5820-9d98-cec770054a06","slug":"complications","fullItemName":"Complications"},{"id":"8ed2c15a-e56e-5667-9aa5-18c0957ec394","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"68029dcd-ffd8-58da-b515-711db2fe0564","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d4c125e5-95c8-5ac3-b5fa-10c5c9889c60","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"026c474a-d688-5999-a8bd-67dd4cb231c3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"55c3f695-d02f-5148-bc68-ddbcddf71e3f","fullItemName":"Management","slug":"management","subChapters":[{"id":"a78bc764-d878-5441-b8d6-cbbcf394ce92","slug":"new-or-initial-management","fullItemName":"Scenario: New or initial management"},{"id":"0266ece8-500b-56bf-8e36-0d23273b3560","slug":"ongoing-management","fullItemName":"Scenario: Ongoing management"}]},{"id":"7355d977-542a-5e6a-9151-82ef7115fa94","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"5dce855c-f4fe-577d-8f55-2d88cdf3a9a4","slug":"dose-titration","fullItemName":"Dose and titration"},{"id":"1df758ad-1fe3-526c-bb06-f19414843379","slug":"switching-antidepressants","fullItemName":"Switching antidepressants"},{"id":"6f10b153-e084-5a21-ae48-3acb33411b10","slug":"toxicity-in-overdose","fullItemName":"Toxicity in overdose"},{"id":"0a0e189c-03e7-5c82-ba71-c96545755eeb","slug":"monitoring-antidepressants","fullItemName":"Monitoring antidepressants"},{"id":"f5deab35-56d4-5f9d-bc07-f29103e961ad","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding"},{"id":"f481ead9-8b60-571b-895e-d927223d993e","slug":"ssris","fullItemName":"SSRIs"},{"id":"83772b94-1512-51dd-99ad-a3fb7725267f","slug":"snris","fullItemName":"SNRIs"},{"id":"299a2937-fa9a-5b97-970b-a79af9a2fc00","slug":"tricyclic-antidepressants","fullItemName":"Tricyclic antidepressants"},{"id":"d4e99efd-b8fb-5453-9c75-f6382c8e25c5","slug":"mirtazapine","fullItemName":"Mirtazapine"},{"id":"3b9d10f7-2760-5bd9-bdf7-92f33416e2c9","slug":"moclobemide","fullItemName":"Moclobemide"},{"id":"823fe65c-0107-5657-8e8f-6ce91ed5cfb6","slug":"reboxetine","fullItemName":"Reboxetine"}]},{"id":"725ab0c0-f1a9-5756-833a-ea5c4f8721bf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"17b06435-7e75-56bf-80c0-57858b6db92c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7eeea9f4-7f32-515a-b661-5f51a513cba7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3907465f-bd0e-530a-b486-c2655ccaba7c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6cef4cda-5622-50b2-9759-9e03266800d3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"59840e87-e4f4-5c49-a6f1-f67d210f3dc0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7d357e2c-3884-5b0c-b9a3-bbf7420da7a9","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3a86a38c-4d81-57f0-ac72-7b5260328853","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"cd426153-dec3-52c5-a8ab-af99800c0ec3","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"683f4417-d586-5c18-9523-48e31114105c","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 96b6d78b-525c-4b28-893e-5022c7d922c8 --><h3>Previous changes</h3><!-- end field 96b6d78b-525c-4b28-893e-5022c7d922c8 -->","summary":null,"htmlStringContent":"<!-- begin item 0b71d2d4-5bda-4ded-beec-4050a58e98d2 --><!-- begin field ba84ad13-3e4f-42a7-98ea-812ef7c1e17c --><p><strong>October 2015 </strong>— minor update. Based on an update to the manufacturer's Summary of Product Characteristics (SPC). Gynaecological haemorrhage and severe and potentially fatal allergic reactions (very rare) have been included as possible adverse effects of paroxetine. The Drug interaction section has been updated to include the possible interaction between selective serotonin reuptake inhibitors (SSRIs) and pravastatin.</p><p><strong>July 2015 </strong>— minor update. Based on an update to the manufacturer's SPC, severe hepatic disorders (with potential fatal outcome) have been included as possible adverse effects of trazodone.</p><p><strong>March 2015 </strong>— minor update. Addition of rhabdomyolysis and urinary retention as adverse effects of mirtazapine.</p><p><strong>October 2014 </strong>— minor update. Addition of constipation as a common adverse effect of mirtazapine.</p><p><strong>April 2014 </strong>— minor update. Update to the link for the BDI depression questionnaire.</p><p><strong>December 2013 </strong>— minor update. Text in management rewritten to clarify that antidepressants should be continued for at least 6 months following remission of symptoms. Typographical errors also corrected.</p><p><strong>July to August 2013 </strong>— reviewed. Literature searches were conducted in July 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The structure of this topic has been changed to improve clarity; however, there are no changes to the recommendations.</p><p><strong>March 2011</strong> — minor update. The NICE quality standards on the management of depression have been added. Issued in June 2011.</p><p><strong>December 2010</strong> — minor update. Expert opinion from UK Medicines Information (UKMI) on the choice of antidepressant in people with epilepsy has been added to the Prescribing information section on <em>Chronic physical health problems</em>. Issued in December 2010.</p><p><strong>October 2010</strong> — minor update. Information on fitness to drive from the Driver and Vehicle Licensing Agency's guidance for medical practitioners, <em>At a glance guide to the current medical standards of fitness to drive</em> has been added. Issued in October 2010.</p><p><strong>June 2010</strong> — minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has advised that epidemiological data show that SSRIs and TCAs are associated with a small increased risk of fractures. However, the mechanism leading to this increased risk is unclear. Issued in June 2010.</p><p><strong>March 2010</strong> — minor update to correct a typographical error in the prescribing information text. Issued in March 2010.</p><p><strong>August 2009 to February 2010</strong> — reviewed. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>March 2009 </strong>— minor update. The Quality and Outcomes Framework (QOF) indicators for depression have been updated in the <em>Goals and outcome measures section</em>. Hypopituitarism following traumatic brain injury has also been included as an underlying cause of depression. Issued in April 2009.</p><p><strong>September 2008</strong> — minor correction to the <em>Changes</em> section. Issued in September 2008.</p><p><strong>November 2007</strong> — updated to include recommendations from NICE technology appraisal <em>Computerised cognitive behavioural therapy for depression and anxiety</em>.</p><p><strong>June 2006</strong> — updated to include amended NICE guidance regarding venlafaxine.</p><p><strong>January 2006 </strong>— updated to include recent advice from the MHRA regarding the safety of paroxetine in pregnancy. Quality and outcomes framework indicators for depression included. Issued in February 2006.</p><p><strong>May 2005</strong> — rewritten. Validated in September 2005 and issued in November 2005.</p><p><strong>April 2004</strong> — updated to include recent advice from the Committee on Safety of Medicines that the recommended target dosage of paroxetine is 20mg daily. Maintenance prescriptions for higher doses have been removed. Issued in July 2004.</p><p><strong>November 2002</strong> — updated to include the management of postnatal depression. Validated in March 2003 and issued in April 2003.</p><p><strong>September 2001</strong> — reviewed. Validated in November 2001 and issued in April 2002. This guidance will be rewritten when the National Institute for Health and Care Excellence (NICE) publishes its guidance on the primary care management of depression, which is anticipated in September 2003.</p><p><strong>August 1998</strong> — written, replacing the guidance <em>Single major depressive episode</em> and <em>Recurrent major depressive episode</em>.</p><!-- end field ba84ad13-3e4f-42a7-98ea-812ef7c1e17c --><!-- end item 0b71d2d4-5bda-4ded-beec-4050a58e98d2 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}